Showing 1 - 3 results of 3 for search 'Lars Mjörnstedt', query time: 0.02s Refine Results
  1. 1
    Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy

    Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy by Pierre Larsson, Bodil Englund, Jana Ekberg, Marie Felldin, Verena Broecker, Lars Mjörnstedt, Seema Baid-Agrawal

    Published 2023-10-01
    Get full text
    Article
  2. 2
    Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

    Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study) by Lillian Streichart, Marie Felldin, Jana Ekberg, Lars Mjörnstedt, Per Lindnér, Annette Lennerling, Verena Bröcker, Johan Mölne, Jan Holgersson, Kristien Daenen, Lars Wennberg, Tomas Lorant, Seema Baid-Agrawal

    Published 2024-03-01
    Get full text
    Article
  3. 3
    Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialPlain-Language Summary

    Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialPlain-Language Summary by Obbo W. Bredewold, MD, Joe Chan, My Svensson, Annette Bruchfeld, Johan W. de Fijter, Hans Furuland, Josep M. Grinyo, Anders Hartmann, Hallvard Holdaas, Olof Hellberg, Alan Jardine, Lars Mjörnstedt, Karin Skov, Knut T. Smerud, Inga Soveri, Søren S. Sørensen, Anton-Jan van Zonneveld, Bengt Fellström

    Published 2023-01-01
    Get full text
    Article

Search Tools: